The Oncosearch | Oncotarget

Gene regulatory network and signalling pathway rewiring: How blood cancer cells shift their shapes to evade drug treatment Editorial

Constanze Bonifer, Peter N. Cockerill

Published Oct 8, 2024 · Vol. 15, No. 1 · pp. 714-716

Keywords: acute myeloid leukaemia, gene regulatory networks, aberrant growth factor signaling, transcription, RUNX1/AP-1 axis

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells Research Paper

Benigno C. Valdez, Bin Yuan, David Murray, Jeremy L. Ramdial, Uday Popat, Yago Nieto, Borje S. Andersson

Published Feb 21, 2024 · Vol. 15, No. 1 · pp. 220-231

Keywords: acute myeloid leukemia, pre-transplant regimens, venetoclax, thiotepa, busulfan

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors Editorial

Giulia Franciosa, Jesper V. Olsen

Published Mar 21, 2023 · Vol. 14, No. 1 · pp. 281-283

Keywords: SHP2, PTPN11, tyrosine, phosphorylation

Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model Research Paper

Hirofumi Tsuzuki, Tatsuya Kawase, Taisuke Nakazawa, Masamichi Mori, Taku Yoshida

Published Dec 13, 2022 · Vol. 13, No. 1 · pp. 1359-1368

Keywords: acute myeloid leukemia (AML), ASP1235, antibody drug conjugate (ADC), venetoclax, azacitidine

Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication Research Paper

Mario Scarpa, Shivani Kapoor, Eric S. Tvedte, Kshama A. Doshi, Ying S. Zou, Prerna Singh, Jonelle K. Lee, Aditi Chatterjee, Moaath K. Mustafa Ali, Robin E. Bromley, Julie C. Dunning Hotopp, Feyruz V. Rassool, Maria R. Baer

Published Aug 2, 2021 · Vol. 12, No. 18 · pp. 1763-1779

Keywords: FLT3 internal tandem duplication, Pim kinase, alternative non-homologous end-joining DNA repair, genomic instability, topoisomerase 2 inhibitors

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach Research Paper

Enric Carcereny, Alonso Fernández-Nistal, Araceli López, Carmen Montoto, Andrea Naves, Cristina Segú-Vergés, Mireia Coma, Guillem Jorba, Baldomero Oliva, Jose Manuel Mas

Published Jan 22, 2021 · Vol. 12, No. 4 · pp. 316-332

Keywords: ALK inhibitor, brigatinib, alectinib, mathematical model, systems biology

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients Research Paper

Mara W. Rosenberg, Kevin Watanabe-Smith, Jeffrey W. Tyner, Cristina E. Tognon, Brian J. Druker, Uma Borate

Published Jun 17, 2020 · Vol. 11, No. 29 · pp. 2807-2818

Keywords: acute myeloid leukemia, drug sensitivity, midostaurin, drug resistance, FLT3

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia Research Paper

Jonathan Canaani, Meital Nagar, Gabriel Heering, Chen Gefen, Ronit Yerushalmi, Noga Shem-Tov, Yulia Volchek, Drorit Merkel, Abraham Avigdor, Avichai Shimoni, Ninette Amariglio, Gidi Rechavi, Arnon Nagler

Published May 24, 2020 · Vol. 11, No. 23 · pp. 2233-2245

Keywords: acute myeloid leukemia, FLT3-ITD, next-generation sequencing

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells Research Paper

Tomoya Aikawa, Noriko Togashi, Koichi Iwanaga, Hiroyuki Okada, Yumi Nishiya, Shinichi Inoue, Mark J. Levis, Takeshi Isoyama

Published Mar 17, 2020 · Vol. 11, No. 11 · pp. 943-955

Keywords: relapsed/refractory AML, FLT3 inhibitors, quizartinib, AC886, midostaurin resistance

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia Correction

Xia Li, Xiufeng Yin, Huafeng Wang, Jiansong Huang, Mengxia Yu, Zhixin Ma, Chenying Li, Yile Zhou, Xiao Yan, ShuJuan Huang, Jie Jin

Published Oct 29, 2019 · Vol. 10, No. 61 · pp. 6641-6642

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Research Paper

Tatsuya Kawase, Taisuke Nakazawa, Tomohiro Eguchi, Hirofumi Tsuzuki, Yoko Ueno, Yasushi Amano, Tomoyuki Suzuki, Masamichi Mori, Taku Yoshida

Published Oct 22, 2019 · Vol. 10, No. 58 · pp. 6111-6123

Keywords: FLT3, FL, FLT3 inhibitor, gilteritinib, antitumor activity

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD⁺ acute myeloid leukemia Research Paper

Yoko Ueno, Masamichi Mori, Yoshiteru Kamiyama, Rika Saito, Naoki Kaneko, Eriko Isshiki, Sadao Kuromitsu, Masahiro Takeuchi

Published Apr 2, 2019 · Vol. 10, No. 26 · pp. 2530-2545

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Martin Grundy, Sahana Balakrishnan, Matthew Fox, Claire H. Seedhouse, Nigel H. Russell

Published Feb 14, 2019

Keywords: AML, BCL-2, MCL-1, Venetoclax, S63845

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Martin Grundy, Sahana Balakrishnan, Matthew Fox, Claire H. Seedhouse, Nigel H. Russell

Published Feb 14, 2019

Keywords: AML, BCL-2, MCL-1, Venetoclax, S63845

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Martin Grundy, Sahana Balakrishnan, Matthew Fox, Claire H. Seedhouse, Nigel H. Russell

Published Dec 28, 2018 · Vol. 9, No. 102 · pp. 37777-37789

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice Research Paper

Colleen E. Annesley, Cara Rabik, Amy S. Duffield, Rachel E. Rau, Daniel Magoon, Li Li, Vicki Huff, Donald Small, David M. Loeb, Patrick Brown

Published Oct 19, 2018 · Vol. 9, No. 82 · pp. 35313-35326

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia Research Paper

Kazuhiro Katayama, Kohji Noguchi, Yoshikazu Sugimoto

Published Sep 28, 2018 · Vol. 9, No. 76 · pp. 34240-34258

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3 Priority Research Paper

Kozo Nagai, Lihong Hou, Li Li, Bao Nguyen, Tessa Seale, Courtney Shirley, Hayley Ma, Mark Levis, Gabriel Ghiaur, Amy Duffield, Donald Small

Published Aug 31, 2018 · Vol. 9, No. 68 · pp. 32885-32899

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia Research Paper

Katrin Schranz, Max Hubmann, Egor Harin, Sebastian Vosberg, Tobias Herold, Klaus H. Metzeler, Maja Rothenberg-Thurley, Hanna Janke, Kathrin BrÃ¤undl, Bianka Ksienzyk, Aarif M.N. Batcha, Sebastian Schaaf, Stephanie Schneider, Stefan K. Bohlander, Dennis GÃ¶rlich, Wolfgang E. Berdel, Bernhard J. WÃ¶rmann, Jan Braess, Stefan Krebs, Wolfgang Hiddemann, Ulrich Mansmann, Karsten Spiekermann, Philipp A. Greif

Published Jul 10, 2018 · Vol. 9, No. 53 · pp. 30128-30145

Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib Research Paper

Rocio I.R. Macias, Anabel SÃ¡nchez-MartÃn, Gabriela RodrÃguez-MacÃas, Luis I. SÃ¡nchez-Abarca, Elisa Lozano, Elisa Herraez, Maria D. Odero, JosÃ© L. DÃez- MartÃn, Jose J.G. Marin, Oscar Briz

Published Jun 19, 2018 · Vol. 9, No. 47 · pp. 28474-28485

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Gene regulatory network and signalling pathway rewiring: How blood cancer cells shift their shapes to evade drug treatment Editorial

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells Research Paper

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors Editorial

Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model Research Paper

Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication Research Paper

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach Research Paper

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients Research Paper

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia Research Paper

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells Research Paper

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia Correction

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Research Paper

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD⁺ acute myeloid leukemia Research Paper

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice Research Paper

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia Research Paper

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3 Priority Research Paper

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia Research Paper

Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Gene regulatory network and signalling pathway rewiring: How blood cancer cells shift their shapes to evade drug treatment Editorial

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells Research Paper

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors Editorial

Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model Research Paper

Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication Research Paper

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach Research Paper

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients Research Paper

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia Research Paper

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells Research Paper

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia Correction

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Research Paper

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia Research Paper

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells Research Paper

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice Research Paper

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia Research Paper

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3 Priority Research Paper

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia Research Paper

Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib Research Paper

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD⁺ acute myeloid leukemia Research Paper